Studies blood and sputum markers that may predict tuberculosis returning in survivors
Looks for markers in blood or sputum that may signal tuberculosis returning in survivors.
Plain-language title generated from the registry record
Registry title: Candidate Clinical Correlate of Prognostic Outcome for TB Study
Key facts
- Where
- Kampala, UgandaSee the 2 sites
Where in Uganda
- Kisenyi Health CenterKampala, UgandaTaking people
- Mulago Outpatient DepartmentKampala, UgandaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT07018076
- Record updated
- 20 July 2026
- Original description
As part of the ongoing efforts within the Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) study, the Candidate Clinical Correlate as Prognostic Outcome for TB (C3PO) study serves as a supplement aimed at evaluating predictors and novel biomarkers of recurrent TB among TB survivors. Current tools for predicting TB recurrence risk are suboptimal, limiting the ability to assess new TB treatment regimens effectively. Identifying accurate sputum- or blood-based biomarkers for recurrence risk could significantly improve the efficiency and informativeness of Phase 2 and 3 clinical trials.Read full original descriptionShow less
Candidate Clinical Correlate of Prognostic Outcome for TB Study
As part of the ongoing efforts within the Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) study, the Candidate Clinical Correlate as Prognostic Outcome for TB (C3PO) study serves as a supplement aimed at evaluating predictors and novel biomarkers of recurrent TB among TB survivors. Current tools for predicting TB recurrence risk are suboptimal, limiting the ability to assess new TB treatment regimens effectively. Identifying accurate sputum- or blood-based biomarkers for recurrence risk could significantly improve the efficiency and informativeness of Phase 2 and 3 clinical trials.
Inclusion: . individuals age ≥ 12 years; . have completed treatment for drug-susceptible tuberculosis with the standard 6-month regimen of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE).
Exclusion: completed treatment for drug-susceptible tuberculosis >14 days prior to screening/enrollment; routinely taking any medication with anti-mycobacterial activity (including fluoroquinolones) for any reason not related to tuberculosis treatment within the last 14 days; unwilling to provide informed consent or return for study follow-up visits.